Medullary thyroid carcinoma (MTC) originates from the parafollicular C cells of the thyroid gland. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC. Germline activating mutations of this gene have been reported in about 88-98% of familial MTCs, while somatic mutations of RET gene have been detected in about 23-70% of sporadic forms. Although these genetic events are well characterized, much less is known about the role of epigenetic abnormalities in MTC.
Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy / Vitale, Giovanni; Dicitore, Alessandra; Messina, Erika; Sciammarella, Concetta; Faggiano, Antongiulio; Colao, Annamaria. - In: RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY. - ISSN 2212-3970. - 11:3(2016), pp. 275-282.
Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
SCIAMMARELLA, CONCETTA;FAGGIANO, ANTONGIULIO;COLAO, ANNAMARIA
2016
Abstract
Medullary thyroid carcinoma (MTC) originates from the parafollicular C cells of the thyroid gland. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC. Germline activating mutations of this gene have been reported in about 88-98% of familial MTCs, while somatic mutations of RET gene have been detected in about 23-70% of sporadic forms. Although these genetic events are well characterized, much less is known about the role of epigenetic abnormalities in MTC.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
